0OCQ Stock Overview
Transgene SA, a biotechnology company, focuses on designing and developing therapeutic vaccines and oncolytic viruses for the treatment of cancer in France.
Snowflake Score | |
---|---|
Valuation | 1/6 |
Future Growth | 2/6 |
Past Performance | 0/6 |
Financial Health | 4/6 |
Dividends | 0/6 |
Transgene SA Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | €1.10 |
52 Week High | €2.30 |
52 Week Low | €1.05 |
Beta | 0.71 |
1 Month Change | -5.00% |
3 Month Change | -19.56% |
1 Year Change | -41.45% |
3 Year Change | -61.20% |
5 Year Change | -62.00% |
Change since IPO | -89.51% |
Recent News & Updates
Recent updates
Shareholder Returns
0OCQ | GB Biotechs | GB Market | |
---|---|---|---|
7D | 5.5% | -1.6% | 0.9% |
1Y | -41.4% | -28.9% | 2.2% |
Return vs Industry: 0OCQ underperformed the UK Biotechs industry which returned -27.3% over the past year.
Return vs Market: 0OCQ underperformed the UK Market which returned 2.7% over the past year.
Price Volatility
0OCQ volatility | |
---|---|
0OCQ Average Weekly Movement | n/a |
Biotechs Industry Average Movement | 7.9% |
Market Average Movement | 4.8% |
10% most volatile stocks in GB Market | 11.1% |
10% least volatile stocks in GB Market | 2.6% |
Stable Share Price: 0OCQ's share price has been volatile over the past 3 months.
Volatility Over Time: Insufficient data to determine 0OCQ's volatility change over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1979 | 143 | Alessandro Riva | https://www.transgene.fr |
Transgene SA, a biotechnology company, focuses on designing and developing therapeutic vaccines and oncolytic viruses for the treatment of cancer in France. It involved in developing TG4050, a therapeutic vaccine that is in Phase I clinical trial for the treatment of ovarian cancer, and head and neck cancers; TG4001, a therapeutic vaccine, which is in Phase II clinical trial for the treatment of HPV-positive cancers; TG6002, an oncolytic virus that is in Phase I/IIa clinical trial for the treatment of gastrointestinal and colorectal cancers; and BT-001, an oncolytic virus, which is in Phase I/II clinical trial for the treatment of solid tumors. The company also develops TG1050, a therapeutic vaccine for the treatment of hepatitis B; TG6050 for the treatment of non-small cell lung cancer, and Pexa-Vec, an oncolytic virus for the treatment of solid tumors.
Transgene SA Fundamentals Summary
0OCQ fundamental statistics | |
---|---|
Market cap | €111.83m |
Earnings (TTM) | -€33.43m |
Revenue (TTM) | €8.91m |
12.6x
P/S Ratio-3.3x
P/E RatioIs 0OCQ overvalued?
See Fair Value and valuation analysisEarnings & Revenue
0OCQ income statement (TTM) | |
---|---|
Revenue | €8.91m |
Cost of Revenue | €31.56m |
Gross Profit | -€22.65m |
Other Expenses | €10.78m |
Earnings | -€33.43m |
Last Reported Earnings
Jun 30, 2023
Next Earnings Date
May 14, 2024
Earnings per share (EPS) | -0.33 |
Gross Margin | -254.29% |
Net Profit Margin | -375.29% |
Debt/Equity Ratio | 52.3% |
How did 0OCQ perform over the long term?
See historical performance and comparison